Wells Fargo raised the firm’s price target on Cencora (COR) to $405 from $354 and keeps an Overweight rating on the shares. The firm says the company reported fairly strong Q4 results and introduced attractive FY26 guidance. Core growth in U.S. Healthcare remains outstanding and absent material deceleration would seem to suggest potential for additional positive estimate revisions, Wells adds.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COR:
- Cencora price target raised to $400 from $350 at TD Cowen
- Cencora price target raised to $371 from $322 at Deutsche Bank
- Cencora price target raised to $415 from $380 at UBS
- Cencora’s Strong Growth Potential and Market Position Justify Buy Rating and Increased Price Target
- Cencora price target raised to $400 from $340 at Evercore ISI